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Abstract
Background: Often researchers are interested in comparing multiple experimental groups (e.g. tumor size) with a
reference group (e.g. normal tissue) on the basis of thousands of features (e.g. genes) and determine if a differentially
expressed feature is up or down regulated in a pairwise comparison. There are two sources of false discoveries, one
due to multiple testing involving several pairwise comparisons and the second due to falsely declaring a feature to be
up (or down) regulated when it is not (known as directional error). Together, the total error rate is called the mixed
directional false discovery rate (mdFDR).
Results: We develop a general powerful mdFDR controlling testing procedure and illustrate the methodology by
analyzing uterine fibroid gene expression data (PLoS ONE 8:63909, 2013). We identify several differentially expressed
genes (DEGs) and pathways that are specifically enriched according to the size of a uterine fibroid.
Conclusions: The proposed general procedure strongly controls mdFDR. Several specific methodologies can be
derived from this general methodology by using appropriate testing procedures at different steps of the general
procedure. Thus we are providing a general framework for making multiple pairwise comparisons. Our analysis of the
uterine fibroid growth gene expression data suggests that molecular characteristics of a fibroid changes with size. Our
powerful methodology allowed us to draw several interesting conclusions regarding the molecular characteristics of
uterine fibroids. For example, IL-1 signaling pathway (Sci STKE 2003:3, 2003), associated with inflammation and known
to activate prostaglandins that are implicated in the progression of fibroids, is significantly enriched only in small
tumors (volume < 5.7 cm3). It appears that the molecular apparatus necessary for fibroid growth and development is
established during tumor development. A complete list of all DEGs and the corresponding enriched pathways
according to tumor size is provided for researchers to mine these data. Identification of these DEGs and the pathways
may potentially have clinical implications.
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Background
Increasingly it is a commonplace for researchers to con-
duct large scale genomic studies involving multiple exper-
imental groups along with a control group, also called
the normal or the reference group. The goal is to deter-
mine features that are differentially expressed in a given
experimental group (relative to the reference group) and
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to determine if a differentially expressed feature is up or
down regulated. For example, a toxicologist may be inter-
ested in identifying differences in the gene expression
profile of spontaneous tumors and chemically induced
tumors, relative to normal tissues [1–4]. There is consid-
erable interest among cancer researchers to understand
the gene expression profile of tumors according to tumor
size [5–9]. Accordingly, this has been an active area of
research for various cancers over the past decade [10, 11].
For example, Gieseg et al. [6] investigated gene expression
of 3 different sizes of colon cancer tumors and found gene
expressions to be constant with tumor size. However, Diaz
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et al. [5] demonstrated that the gene expression of β4 inte-
grin is correlated with both size and nuclear grade of the
breast cancer tumors, with increased expression in large
tumors and in higher tumor grades. More recently Riis
et al. [9] conducted an extensive gene expression analysis
of breast cancer tumors according to size categories and
identified genes and activation pathways that were spe-
cific to tumor size. They concluded that the molecular
signatures derived from their analysis will help clinicians
determine whether to treat tumors of a given size category
aggressively or not. Earlier Ciarmela et al. [12] conducted
an exhaustive study of the role of various growth fac-
tors on the development of uterine fibroids (leiomyoma).
Thus it is clear there is considerable interest among clini-
cians and biologists to investigate the expression of genes
according to the tumor size or category. In all such inves-
tigations, one is typically interested in performing several
pairwise comparisons, of thousands of features, relative to
a reference group (e.g. normal tissue). Often researchers
are not only interested in determining if a feature is differ-
entially expressed but are also interested in determining
whether it is up or down-regulated in the experimen-
tal group (relative to the reference group). For simplicity
of exposition, throughout this paper we shall replace the
term “feature” by “gene”.
Multiple testing problems involving multiple pairwise
comparisons of high dimensional data along with direc-
tional decisions has not received much attention in
the literature, yet such testing problems are commonly
encountered in practice. When the number of genes
is very small (perhaps in tens) several methods have
been proposed that control the directional errors as well
as the family wise error rate [13–16]. However, such
methods are very conservative when the number of genes
is very large as in a microarray data or CpG methylation
data [37–38]. Several ad-hoc methods and strategies are
used in the literature when the number of genes is large.
For example, some researchers apply multiple testing pro-
cedures (e.g. the Benjamini-Hochberg (BH) or Bonferroni
procedure) within each pairwise comparison and ignore
the fact that they are conducting several pairwise com-
parisons. Once a differentially expressed gene (DEG) for
a pairwise comparison is identified then they are declared
to be up or down-regulated by looking at the direction of
the fold change (or the test statistic) without accounting
for the statistical error associated with such a direc-
tional decision. Such strategies result in an inflated over-
all error rate due to multiple pairwise comparisons and
directional decisions. This overall error rate is called the
mixed directional false discover rate (mdFDR). Another
procedure that is commonly used by researchers is to
first perform ANOVA across all experimental groups
for each feature. Using the resulting p-values, a multi-
ple testing procedure is applied to obtain an initial list
of DEGs. These DEGs are then subject to a Tukey’s test
or a Bonferroni test to identify the pairwise compar-
isons where a DEG is significant. The directional decision
regarding whether a gene is up or down regulated, is
made on the basis of the direction of the fold change.
While this strategy is more intuitive than the earlier
one, it is potentially a conservative procedure resulting
in a substantial loss of power, firstly because intrinsi-
cally ANOVA compares all treatment groups. Secondly,
the thresholds or the critical values at the two steps
are not derived with the goal to control the overall
error rate.
The only formal methodology available in the literature
that controls the mdFDR for the above directional mul-
tiple testing problems is the method by Guo et al. [17],
which is designed to make decisions on thousands of fea-
tures when making multiple pairwise comparisons and
deciding on the direction of comparison. Thus themethod
controls the false discovery rate when making multiple
pairwise comparisons on thousands of genes while also
controlling the directional errors committed when falsely
declaring a DEG to be up-regulated (or down-regulated)
when it is not. Guo et al. [17] procedure generalizes
the procedure of Benjamini and Yekutieli [18] which was
designed for the case when there were only two groups
to compare. The procedure of Guo et al. [17] is avail-
able in the software ORIOGEN (3.2) that can be accessed
from http://www.niehs.nih.gov/research/atniehs/labs/bb/
staff/peddada/.
While Guo et al. [17] methodology is useful for mak-
ing several multiple pairwise comparisons; it is relatively
conservative since it relies on the Bonferroni procedure
to deal with multiple pairwise comparisons within each
gene. In this paper we develop a general mdFDR control-
ling testing procedure that allows us to use any mixed
directional familywise error rate (mdFWER) controlling
procedure in place of the Bonferroni procedure, for con-
ducting pairwise comparisons in high dimensional data
that is broadly applicable to a wide range of genomic data
including gene expression microarray data, CpG methy-
lation data, RNA-seq data and others. Based on this gen-
eral procedure, we develop a specific methodology using
the Dunnett’s test [19–21] which is designed for making
comparisons of several experimental groups with the con-
trol or the reference group. Not only that the resulting
methodology is practically relevant but as demonstrated
in the numerical simulations, the resulting methodology
not only controls themdFDR but is more powerful relative
to some potential alternative methods.
We illustrate the proposed methodology by analyz-
ing a gene expression data obtained from the NIEHS’
Fibroid Growth Study (FGS) [22]. Using our methodol-
ogy we gain deeper insights into molecular character-
istics of uterine fibroids according to the tumor size,
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which was not understood until now. We have identified
several differentially expressed genes and pathways that
are specifically enriched according to the tumor size.
While researchers and clinicians who study fibroids are
well aware of many of the genes and pathways described
in this paper, we have provided a characterization of these
genes and pathways according to the tumor size. Our data
can be further mined to gain deeper insights regarding
fibroids.
Methods
In this section we present the general testing procedure
that controls mdFDR while making multidimensional
directional decisions, and develop the statistical method-
ology based on Dunnett’s test that is used to analyze FGS
gene expression data. The relevant notations, definitions,
hypotheses and other statistical concepts are described in
the online Additional file 6 (see Sections S1 and S3) and
Additional file 1: Figure S1.
The general mdFDR controlling procedure
The general testing algorithm:
1. Use any global testing method to obtain the
screening p-values. Apply BH procedure [23] to
identify genes that are differentially expressed in at
least one pairwise comparison. Let R denote the
number of genes so discovered.
2. For each gene discovered in step 1, use any
two-sample testing method to obtain the p-values for
each pairwise comparison and apply any mixed
directional family wise error (mdFWER) controlling
procedure, such as Holm, Hochberg etc. [24, 25], to
the pairwise p-values at level Rα/m.
3. For a given gene discovered in step 1, if a pairwise
hypothesis is rejected in step 2, then we declare the
gene to be up or down regulated in the pairwise
comparison according to the sign of the
corresponding test statistic.
This procedure is general in the sense that any global
testing method can be used to obtain the screening p-
values in step 1 of the procedure, any pairwise comparison
testing method can be used to obtain the pairwise p-
values in step 2 and any mdFWER controlling procedure
can be used in steps 2-3 of the procedure. It is impor-
tant to note here that the method of Guo et al. [17] is a
special case of the proposed general procedure in which
Bonferroni global test is used for testing the screening
hypotheses and Bonferroni method along with additional
directional decisions works as the mdFWER controlling
procedure. This general algorithm is proved to control
mdFDR through the following theorem with the math-
ematical proof provided in the online Additional file 6:
Section S2.
Theorem 1. Under assumption of independence of
p-value vectors Pj, j = 1, . . . ,m, the mdFDR of the
General Testing Algorithm is strongly controlled at
level α.
Statistical methodology for FGS gene expression data
Suppose we are interested in comparing “q” experimen-
tal groups with a reference group (in total p = q + 1
groups) on the basis of the mean expression of “m” genes.
For example, suppose we are interested in comparing
“small”, “medium” and “large” fibroids with a “normal”
tissue (also called normal myometrium) from uterus on
the basis of “m” genes. Our goal is not only to identify
differentially expressed genes in any given pairwise com-
parison but also to determine if the mean expression is
up or down-regulated in the tumor tissue compared to
the normal myometrium. Our statistical methodology for
the FGS gene expression data analysis proceeds in three
steps as follows. Specific details of implementation of
each step are described in the online Additional file 6:
Section S3.
1. For each gene we obtain a Dunnett [19–21] based
screening p-value from all “q” pairwise comparisons
with the reference group. This results in one p-value
for each gene. Applying the BH procedure [23] on
these screening p-values, we obtain genes that are
differentially expressed in at least one pairwise
comparison. Suppose we discover R genes in this
step. Thus there are R genes which are differentially
expressed in at least one pairwise comparison with
the reference group.
2. For the jth gene discovered in Step 1, we compute
Dunnett’s p-value Pij for each pairwise comparison i,
i = 1, 2, . . . , q, with the reference group. If Pij ≤ Rαm
then we declare that the ith pairwise comparison with
the reference group is significant.
3. If a gene j is found to be significant in the ith pairwise
comparison with the reference group then we declare
it to be up-regulated in the ith group relative to the
reference group if Tij > 0, otherwise it is declared to
be down-regulated. Here Tij denotes the test statistic
associated with the jth gene in the ith pairwise
comparison.
Remarks. It is important to note in Steps 1 and 2 that it
is possible for a gene to be differentially expressed on the
basis of the screening p-value, yet it may not be significant
in any of the pairwise comparisons. This happens when
the BH-adjusted p-values are only marginally significant.
In such cases we declare that gene to be not differentially
expressed.We expect this phenomenon to occur with very
small frequency.
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Results and discussion
In this section we present two sets of numerical results.
First, the operating characteristics of the proposed pro-
cedure based on a simulation study are presented. Next,
we apply the proposed methodology to a gene expression
data obtained from the NIEHS’ FGS to identify tumor size
specific DEGs.
Numerical simulation and discussion
In this section we present the operating characteris-
tics of the proposed procedure based on a simulation
study. This study evaluates the power of the proposed
Dunnett based methodology and compares its perfor-
mance with some competing procedures, the details
of which are given in the online Additional file 6:
Section S4.
In our simulation we considered p = 4 groups, the
first three were taken to be experimental groups and the
last group was taken to be the reference group. Thus all
pairwise comparisons are made with the last group. Our
simulated microarray chip consisted of m = 1000 genes
per chip with n = 10 chips per group. As often done
in simulation studies for microarray data [17, 26–28], we
generated the expression of each gene in each chip using a
normal distribution.
More precisely, for the jth gene, j = 1, 2, . . . , 1000, in the
sth sample, s = 1, 2, . . . , 10 in the gth group, g = 1, 2, 3, 4,
we generated its expression Zsgj from a normal distribution









For the reference group (i.e. group 4) we set μ4j = 0
for all j. To create the null data we set μgj = 0 for j =
1, 2, . . . ,m0, g = 1, 2, 3 and non-null data were created by
generating μgj ∼independent U(0, 2.5), for g = 1, 2, 3 and
j = m0 + 1,m0 + 2, . . . ,m0 + m1, where m1 = m − m0
andU represents the uniform distribution. It is important
to note that, for the non-null means considered here, the
standard deviation used in this simulation study is large.
Consequently, all methods considered in this simulation
study are expected to have small power. We considered
three patterns of correlation structure as follows: (a) Inde-
pendent gene expressions: the correlation coefficient ρ
between any pair of genes and any pair of sample is 0, thus,
the data are completely independent. (b) Gene expressions
within sample are dependent: for a given sample s, the cor-
relation coefficient between any pair of genes is ρ but the
correlation coefficient between any pair of samples is 0. (c)
Gene expressions within genes are dependent: for a given
gene j, the correlation coefficient between any pair of sam-
ples is ρ but the correlation coefficient between any pair of
genes is 0. Although we considered a variety of patterns of
ρ, due to space limitations we only present the results cor-
responding to independence. Similar results are obtained
for other patterns of ρ (see the online Additional file 6:
Section 4 for the results).
We simulated the mdFDR and average power using
1000 simulation runs. Our nominal mdFDR level was
taken to be α = 0.05. Details regarding the calcu-
lations of the mdFDR and power are provided in the
accompanying online Additional file 6. For comparison
purposes, we compared the proposed procedure with the
Guo et al. [17] procedure and variants of the proposed
procedure in which the mdFWER controlling procedures
used in steps 2 and 3 of the algorithm are respectively,
the Holm’s procedure [24], the Hochberg’s procedure [25]
and the Bonferroni procedure. These procedures are
described in detail in the online Additional file 6.
We summarize the results of the simulation studies in
Fig. 1 for the independence case. The horizontal axis
denotes the proportion of truly differentially expressed
genes on the array and the vertical axis denotes the aver-
age mdFDR (left panel) and average power (right panel).
As desired, all five procedures control the mdFDR on
average at α = 0.05. However, the proposed Dunnett
based procedure has highest power compared to all other
methods considered
We summarize the results for the case of dependence
within genes across groups in Fig. 2, Additional file 2:
Figure S2 and Additional file 3: Figure S3 and the results
for the case of dependence among genes in Fig. 3, Addi-
tional file 4: Figure S4 and Additional file 5: Figure S5.
The details of these dependence structures are given in
the online Additional file 6: Section S4. Although all five
procedures control the mdFDR on average at 0.05, the
power of our proposed methodology is much higher com-
pared to all four competing procedures under the different
dependence structures considered.
Analysis of gene expressions in uterine fibroids
Uterine fibroids are benign smooth muscle tumors occur-
ring in the uterus of women with a very high prevalence
rates in many populations. These tumors are considered
to be hormonally mediated and therefore occur during the
pre-menopausal years. According to some estimates, the
cumulative incidence by age 50 of these tumors among
Caucasian women exceeds 70% and it is much higher
among women of African American descent. The direct
and indirect annual cost of fibroids in the US is as
high as 34 billion dollars, yet these tumors are not well-
studied perhaps because they are considered to be benign.
The NIEHS conducted a large prospective study track-
ing the growth of fibroids in 72 pre-menopausal women
over 12 months and discovered difference in growth pat-
terns of fibroids according to age for white and black
women [22]. A total of 52 tumor samples and 8 normal
myometrium samples were collected from 12 women who
opted for either hysterectomy or myomectomy. The RNA
from these tissue samples were processed to obtain gene
expression data using Affymetrix chips (Human Genome
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Fig. 1mdFDR (left), Average Power (right). mdFDR (left), Average Power (right) with the proposed methodology and three variants using Holm,
Hochberg and Bonferroni procedures, respectively, in steps 2 and 3 along with Guo et al. [17] procedure, under independence among genes and
within genes
U133 plus 2.0). A total of 54675 probe sets were obtained.
Using these gene expression data Davis et al. [29] studied
the molecular characteristics of fibroids. Several impor-
tant DEGs and canonical pathways were identified in
Davis et al. [29], which were also experimentally validated
using RtPCR.
In this paper we take the next step towards the under-
standing of molecular characteristics of fibroids by inves-
tigating the changes in gene expression according to
tumor size. As done in the literature for other tumors
such as breast cancer tumors and others [5–9], we are
interested in identifying genes that are specific to size
of uterine fibroids. We classified fibroids into three size
groups according to their volume, small (14 samples,
volume: 0.08–5.70 cm3), medium (25 samples, volume:
9.0–132.00 cm3) and large (13 samples, volume: 240-2016
cm3) and compared each size category with the normal
myometrium, the reference group, using the proposed
Fig. 2mdFDR (left), Average Power (right). mdFDR (left), Average Power (right) with the proposed methodology and three variants using Holm,
Hochberg and Bonferroni procedures, respectively, in steps 2 and 3 along with Guo et al. [17] procedure, under dependence (ρ = 0.2) within genes
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Fig. 3mdFDR (left), Average Power (right). mdFDR (left), Average Power (right) with the proposed methodology and three variants using Holm,
Hochberg and Bonferroni procedures, respectively, in steps 2 and 3 along with Guo et al. [17] procedure, under dependence (ρ = 0.2) among genes
Fig. 4 Volume of fibroids according to size category
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methodology. The cut points between size categories were
chosen so that there is a natural separation between the
size categories. The sorted volumes of the 52 tumors are
provided in Fig. 4. Due to large differences in the volumes
between large and small tumors, for clarity we provided
volumes in three panels according to their size.
We identified a total of 9553 probe sets to be differ-
entially expressed in at least one pairwise comparison
(relative to the normal myometrium) at mdFDR of 0.05.
These 9553 probe sets map to 6286 genes. The Venn dia-
gram of the DEGs by tumor size is in Fig. 5. Based on the
6286 genes, using the Ingenuity Pathway Analysis (IPA,
2000-2014 QIAGEN), we discovered a total 157 distinct
enriched canonical pathways. The Venn diagram of the
number of enriched canonical pathways by tumor size is
provided in Fig. 6.
It is not surprising that a third of the DEGs and nearly
30% of all enriched pathways are common to tumors of all
sizes since tumor tissues are fundamentally different from
the normal myometrium. However, we discover several
DEGs and pathways that are uniquely enhanced according
to the tumor size, suggesting that changes in molecular
characteristics might be taking place as tumors grow. We
highlight some important groups of genes and pathways
discovered by our methodology and provide the complete
list of all genes and pathways in the Additional files 7
and 8, respectively, for researchers to mine our data. The
“Gene Symbol” and “Gene Name” columns in these tables
are obtained from the website DAVID (http://david.abcc.
ncifcrf.gov/).
Growth factors, vascularization and related pathways:
The Netrin signaling pathway is well-known as a versatile
Fig. 5 Venn diagram of differentially expressed genes by tumor size
Fig. 6 Venn diagram of enriched pathways by tumor size
pathway with multiple functions. One of its functions is
to promote vascular networks and branching of blood
vessels [30] and angiogenesis [31]. According to our anal-
ysis this pathway is uniquely enriched in small tumors
only. The Interleukin-1 (IL-1) pathway is known to
induce inflammatory response and the production of
prostaglandins and expression of IL-2 which may play a
critical role in the fibroid initiation and early develop-
ment. For example, prostaglandins play a critical role in
the promotion of growth factors involved in angiogene-
sis, such as VEGF, basic fibroblast growth factor (bFGF)
and platelet-derived growth factor (PDGF) [32] and devel-
opment of fibroid requires vascularization and blood
supply. Thus Interleukin-1 (IL-1) pathway likely plays
an important role during fibroid development. Interest-
ingly, according to our analysis, this pathway is uniquely
enriched in small size tumors but not in the medium or
large tumors (Additional file 8). Furthermore, the fibrob-
last growth factors 8 and 20 (FGF8, FGF20) which belong
to the Regulation of the Epithelial-Mesenchymal Transi-
tion Pathway and are well-known to be involved in vas-
cularization and angiogenesis, are both uniquely down-
regulated in small tumors and not differentially expressed
in medium or large tumors. Our analysis further implies
that the Epithelial-Mesenchymal Transition Pathway was
enriched only in small and medium size tumors.
According to Ciarmela et al. [12], estrogen may pro-
mote fibroid growth through up-regulation of epidermal
growth factor receptor (EGFR). However, we found EGFR
to be down-regulated in fibroids and that too only in the
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medium size tumors. Similarly, the fibroblast growth fac-
tors (FGF) (acidic and basic) were differentially expressed
only in the medium size tumors. The acidic FGF was
up-regulated whereas the basic FGF was down regulated.
These findings are consistent with Ciarmela et al. [12]
(and references therein, e.g. Wolanska et al. [33]) in that
they are expressed during tumor progression. Similarly,
insulin like growth factor (IGF1) was only differentially
expressed (up-regulated) in medium size tumors. Addi-
tionally, growth factor signaling pathways such as VEGF,
PDGF, TGFβ and EGF are uniquely enriched in medium
size tumors and not in small or large tumors. While the
above results suggest that some growth factors and related
pathways are very specific to small and medium tumors,
we discovered several growth factors to be differentially
expressed in tumors of all sizes. These included, insulin
like growth factor 2 (INS-IGF2), insulin like growth factor
binding protein 5 (IGFBP5), and platelet derived growth
factor C (PDGFC) which were up-regulated whereas
insulin-like growth factor binding protein 6 (IGFBP6),
connective tissue growth factor (CTGF), heparin-binding
EGF-like growth factor (HBEGF), transforming growth
factor beta receptor II (TGFBR2), fibroblast growth fac-
tors 12 and 13 (FGF12, FGF13) were down-regulated.
Similarly, growth factor signaling pathways such as the
human growth factor (HGF) and IGF-1 were enriched in
tumors of all sizes. Thus it appears that the differential
expression of these genes and the enrichment of the above
pathways is necessary for tumor onset and progression.
Estrogen and related genes: Fibroids are hormonally
mediated and it is also well documented in the litera-
ture that accordingly estrogen and progesterone recep-
tors and prostaglandins promote proliferation of fibroids
(see [29, 34]). Not surprisingly, we found the estrogen
receptor ESR-1 to be up-regulated in tumors of all sizes.
This result was confirmed using the RtPCR data (see
Additional file 9). Our RtPCR data further indicates that
the expression of ESR-1 in small tumors is almost 38%
higher than in large tumors, suggesting that ESR-1 has
a large effect on small tumors but is also needed for
the continued growth of the tumor. Interestingly, the
progesterone receptor (PGR) was up-regulated in only
medium size tumors and not differentially expressed in
small or large tumors, a result that is also confirmed
by the RtPCR (Additional file 9). This suggests that
perhaps PGR may not be involved in tumor initiation
(i.e. small tumors) but is only involved in growth of
the tumor. However, its function ends once the tumor
becomes large enough. Most prostaglandins were gener-
ally down-regulated in tumors of all sizes. For example,
prostaglandin E receptor 3 (PTGER3), prostaglandin F
receptor (PTGFR) and prostaglandin-endoperoxide syn-
thase 2 (prostaglandin G/H synthase and cyclooxyge-
nase) (PTGS2) are down-regulated in tumor of all sizes.
The result of PTGS2 was also confirmed using RtPCR
(see Additional file 9). However, some prostaglandins
were differentially expressed according to the size of
the tumor. For example, prostaglandin-endoperoxide syn-
thase 1 (prostaglandin G/H synthase and cyclooxyge-
nase) (PTGS1) was differentially expressed only in the
medium sized tumors where it was down-regulated and
prostaglandin E synthase 2 (PTGES2) was down-regulated
in large tumors only but prostaglandin E receptor 4
(PTGER4) was down-regulated in both medium and large
tumors.
Similar to estrogen and progesterone receptors, the
α and γ isoforms of peroxisome proliferator-activated
(PPAR) receptors have been associated with the regula-
tion of proliferation of uterine fibroids [35, 36]. In our
data both these isoforms are down-regulated in all tumor
sizes compared to the normal myometrium. We also dis-
covered the related retinoid X receptor gamma to be
down-regulated in the medium size tumors but was not
significant in small or large tumors.
Collagens: There is a vast amount of literature impli-
cating collagens to smooth muscle tumors such as
the fibroids (see [29], and references therein). Con-
sequently, it is not surprising that several collagens
(COL1A1, COL1A2, COL3A1, COL4A1-COL4A4,
COL5A2, COL6A3, COL7A1, COL9A2, COL21A1,
COL22A1, COL27A1) and extra cellular matrix proteins
are differentially expressed in tumors of all sizes. Apart
from COL4A3, COL4A4 and COL21A1, which were
down-regulated in all tumor size groups, the remaining
11 collagens were up-regulated in tumor samples. We
investigated a subset of these collagens using RtPCR
which confirmed the above findings for those genes (see
Additional file 9). There were other collagens that were
differentially expressed depending upon the size of the
tumor. For example, COL2A1, COL4A6 and COL5A1
were not differentially expressed in small tumors but were
significantly up-regulated in medium and large tumors.
Collagen COL23A1 was significantly up-regulated in
small and medium tumors but not in the large fibroids.
Interestingly, some of the collagens were differentially
expressed in only one of the size categories. For exam-
ple, COL4A3BP, COL6A1, COL9A3, COL10A1 and
COL11A1 were differentially expressed only in the large
tumors. Again, except for COL4A3BP, the remaining
4 collagens were up-regulated in the tumor samples.
Interestingly, COL5A3 was only differentially expressed
(down-regulated) in small tumors.
Other genes: Leptin receptor is well-known to be nega-
tively associated with the obesity and obesity is a potential
risk factor for fibroids. Interestingly, we discover lep-
tin receptor (LEPR) to be significantly down-reglated
in all tumor sizes. This finding is also confirmed by
the RtPCR data reported in Additional file 9. As noted
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earlier, Diaz at al. [5] demonstrated that β4 integrin had
an increased expression in larger breast tumors and in
higher tumor grades. In our fibroid data, however, we
notice a down-regulation in β4 integrin in medium and
large tumors and was not differentially expressed in small
tumors.
Comparison of various procedures with Dunnett’s test
based methodology
We analyzed the NIEHS FGS data using various meth-
ods considered in this paper at mdFDR level of 0.05.
We compared the methods in terms of number of probe
sets that were differentially expressed (relative to nor-
mal myometrium) in; (a) all tumors, (b) small tumors, (c)
medium tumors, and (d) large tumors. Results are sum-
marized using Venn diagrams. In Fig. 7 we compare our
Dunnett test based methodology with Guo et al. [17]
procedure. Not only did the Dunnett based methodol-
ogy identified many of the probe sets identified by the
Guo et al. [17] procedure, i.e. shared several probe sets
(overall = 7911, small = 5042, medium = 6728, large =
2341), it identified several more that were not identified
by Guo et al. [17] procedure (overall = 1642, small =
2061, medium = 1112, large = 1986). On the contrary,
there were very few probe sets that were uniquely identi-
fied by Guo et al. [17] procedure (overall = 695, small =
445, medium = 529, large = 316). We see similar results
when we compare Dunnett screening and Holm proce-
dure (Holm), Dunnett screening and Hochberg procedure
(Hochberg) and Dunnett screening and Bonferroni proce-
dure (Bonferroni). The Venn diagram in Fig. 8 compares
the number of probe sets identified by Dunnett based
method to each of the other methods. In each case the
Dunnett based method tends to uniquely identify many
probe sets than each of the other methods. The total num-
ber of probe sets identified by the various methods are
summarized in Table 1.
Conclusion
This paper offers a general statistical methodology for
conducting pairwise comparisons in high dimensional
data that is broadly applicable to a wide range of genomic
data including gene expression microarray data, CpG
methylation data, RNA-seq data and others and proposes
a specific testingmethodology for the analysis of FGS gene
expression data. The proposedmethodology not only con-
trols the false discoveries made when making several pair-
wise comparisons on the basis of high dimensional data,
Fig. 7 Venn diagram of identified probe sets by the Dunnett based methodology and Guo et al. [17] method. The Venn diagrams compare the two
procedures in terms of the probe sets identified in at least one tumor size, Large tumor size (irrespective of being identified in medium or small
tumor sizes), Medium tumor size (irrespective of being identified in Large or Small tumor sizes) and Small tumor size (irrespective of being identified
in Large or Medium tumor sizes)
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Fig. 8 Venn diagram of identified probe sets by the Dunnett based methodology and other methods discussed in numerical studies. The other
methods considered in the numerical simulation are Dunnett screening and Holm procedure (Holm), Dunnett screening and Hochberg procedure
(Hochberg) and Dunnett screening and Bonferroni procedure (Bonferroni)
but it controls for directional errors, i.e. falsely declar-
ing a gene to be up-regulated (down-regulated) when it
is not. Thus it controls the mixed directional false dis-
covery rate (mdFDR). The framework we proposed here
is general enough that, depending upon the application,
a researcher can use different testing procedures within
our framework. In all situations the procedure strongly
controls mdFDR. For the application under consideration
in this paper, the experimental design calls for the compar-
ison of several experimental groups against a particular
group. For such designs, in the classical multiple compar-
ison problem, the Dunnett’ test is known to be powerful.
So, it is not surprising that our Dunnett’s test based pro-
cedure is most powerful among all the procedures we
considered in this paper. Ourmethodology based on Dun-
nett procedure works best here in terms of power because
(a) the Dunnett’s p-values are based on the joint distribu-
tion of the test statistics and (b) our procedure uses the
maximum order statistic to find the screening p-value.
Using our methodology we gain deeper insights into
molecular characteristics of uterine fibroids according
to the tumor size. We have identified several differen-
tially expressed genes and pathways that are specifically
enriched according to the tumor size. While researchers
and clinicians who study fibroids are well aware of many
of the genes and pathways described in this paper, we
have provided a characterization of these genes and path-
ways according to the tumor size. Our data can be further
Table 1 Probe sets identified by our suggested Dunnett based method, Guo et al. [17] method and other possible methods
Dunnett based Guo et al. Holm Hochberg Bonferroni
At least one tumor size 9553 8606 8064 8139 8064
Large tumors only 1180 922 503 483 697
Medium tumors only 1548 2303 1557 1489 1976
Small tumors only 427 349 175 162 224
Large and Medium tumors only 2498 2724 2168 2189 2712
Large and Small tumors only 106 78 40 45 77
Medium and Small tumors only 475 467 331 339 475
All tumor sizes 3319 1763 3290 3432 1903
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mined to gain deeper insights regarding fibroids. In view
of the recent publication [29] we acknowledge that our
results are potentially confounded by race. Since the sam-
ple size by race is very small, we are unable to separate out
the race effect. Despite that potential weakness, we think
that our findings provoke researchers to explore further
research along these lines.
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